Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing oral small-molecule therapies for neurologic, gastrointestinal, inflammatory and autoimmune diseases. Its lead candidate, vidofludimus calcium, is in Phase 3 development for relapsing multiple sclerosis and is also being evaluated for progressive forms… From the company’s description.
In fiscal 2025, Immunic, Inc. reported a net loss of $97.17M. Operations used $85.81M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Immunic, Inc. does
In the company’s own words
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing oral small-molecule therapies for neurologic, gastrointestinal, inflammatory and autoimmune diseases. Its lead candidate, vidofludimus calcium, is in Phase 3 development for relapsing multiple sclerosis and is also being evaluated for progressive forms of the disease; the company acquired the asset in 2016 from 4SC AG. IMU-856, licensed for global commercialization from Daiichi Sankyo, targets intestinal barrier function and bowel epithelial regeneration and has been studied in celiac disease. IMU-381 is a preclinical program based on the company’s Nurr1 platform, while its wholly owned subsidiary Gliomic Therapeutics pursues compounds for brain cancers. Immunic has no approved products and reports no operating segments or product sales. It had 92 employees as of February 1, 2026, and its research and development operations are based primarily in Germany, with additional activity in Australia. Its website is https://imux.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, X1
- Fiscal year end
- December
- CIK
- 1280776
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Immunic, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Immunic, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Immunic, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Immunic, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Immunic, Inc.'s last four quarterly filings that the numbers alone won't show?”